Literature DB >> 10893838

The role of radioactive iodine in salivary gland dysfunction.

K A Newkirk1, M D Ringel, L Wartofsky, K D Burman.   

Abstract

The use of radioactive iodine has become an important adjunct to the treatment of thyroid cancer. Many normal tissues--including salivary glands, gastrointestinal mucosa, gonads, and lactating breast tissue--have the ability to concentrate radioactive iodine under normal circumstances. Although the mechanism is just beginning to be elucidated, it is this ability that might contribute to the immediate and long-term complications associated with radioactive iodine treatment. In some patients, the salivary complications can be permanent and might compromise daily functioning. In this article, we examine the salivary gland complications associated with radioactive iodine therapy, and we suggest potential protective mechanisms to circumvent these problems.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10893838

Source DB:  PubMed          Journal:  Ear Nose Throat J        ISSN: 0145-5613            Impact factor:   1.697


  9 in total

1.  Assessment of salivary gland dysfunction after radioiodine therapy for thyroid carcinoma using non-contrast-enhanced CT: the significance of changes in volume and attenuation of the glands.

Authors:  B Nabaa; K Takahashi; T Sasaki; A Okizaki; T Aburano
Journal:  AJNR Am J Neuroradiol       Date:  2012-05-03       Impact factor: 3.825

2.  Nasal symptoms after radioiodine therapy: a rarely described side effect with similar frequency to lacrimal dysfunction.

Authors:  Jacqueline Jonklaas
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

3.  Modulation of sodium/iodide symporter expression in the salivary gland.

Authors:  Krista M D La Perle; Dong Chul Kim; Nathan C Hall; Adam Bobbey; Daniel H Shen; Rebecca S Nagy; Paul E Wakely; Amy Lehman; David Jarjoura; Sissy M Jhiang
Journal:  Thyroid       Date:  2013-07-17       Impact factor: 6.568

Review 4.  RETRACTED ARTICLE: Radiation sialadenitis induced by high-dose radioactive iodine therapy.

Authors:  Shin Young Jeong; Jaetae Lee
Journal:  Nucl Med Mol Imaging       Date:  2010-04-21

5.  Salivary Function after Radioiodine Therapy: Poor Correlation between Symptoms and Salivary Scintigraphy.

Authors:  Jacqueline Jonklaas; Hong Wang; Giuseppe Esposito
Journal:  Front Endocrinol (Lausanne)       Date:  2015-06-17       Impact factor: 5.555

6.  Effects of first radioiodine ablation on functions of salivary glands in patients with differentiated thyroid cancer.

Authors:  Arun Upadhyaya; Zhaowei Meng; Peng Wang; Guizhi Zhang; Qiang Jia; Jian Tan; Xue Li; Tianpeng Hu; Na Liu; Pingping Zhou; Sen Wang; Xiaoxia Liu; Huiying Wang; Chunmei Zhang; Fengxiao Zhao; Ziyu Yan
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

7.  Disorders of Dental Hard Tissues Induced by Radioiodine-131 (I-131) Therapy Used in Differentiated Thyroid Cancer: An In Vitro Study.

Authors:  Alexandru Mester; Andra Piciu; Doina Piciu; Ioan Petean; Patricia Ondine Lucaciu; Dragos Apostu; Cristina Moisescu-Goia; Andrada Voina-Tonea; Marioara Moldovan
Journal:  Biomedicines       Date:  2020-11-05

Review 8.  Salivary duct stenosis: diagnosis and treatment.

Authors:  M Koch; H Iro
Journal:  Acta Otorhinolaryngol Ital       Date:  2017-04       Impact factor: 2.124

9.  Pilocarpine used to treat xerostomia in patients submitted to radioactive iodine therapy: a pilot study.

Authors:  Juliana Pereira Almeida; Luiz Paulo Kowalski
Journal:  Braz J Otorhinolaryngol       Date:  2010 Sep-Oct
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.